Kiniksa Pharmaceuticals, Ltd. (KNSA) Financial Ratios
10 years of historical data (2016–2025) · Healthcare · Biotechnology
EV/EBITDA
↓
51.65
↓-11% vs avg
5yr avg: 58.21
30Y Low39.4·High77.1
P/FCF
↓
166.24
↑+43% vs avg
5yr avg: 116.15
30Y Low55.6·High185.0
P/B Ratio
↑
7.92
↑+110% vs avg
5yr avg: 3.77
30Y Low2.7·High5.7
ROE
↑
11.7%
↓+1121% vs avg
5yr avg: 1.0%
30Y Low-64%·High63%
Debt/EBITDA
↓
0.12
↓-60% vs avg
5yr avg: 0.30
30Y Low0.1·High0.5
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
KNSA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Kiniksa Pharmaceuticals, Ltd. trades at 75.9x earnings, 53% above its 5-year average of 49.5x, sitting at the 67th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a premium of 240%. On a free-cash-flow basis, the stock trades at 166.2x P/FCF, 43% above the 5-year average of 116.1x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4.2B | $3.3B | $1.4B | $1.3B | $1.1B | $807M | $1.1B | $598M | $830M | — | — |
| Enterprise Value | $4.1B | $3.1B | $1.2B | $1.2B | $938M | $691M | $986M | $554M | $523M | — | — |
| P/E Ratio → | 75.91 | 55.00 | — | 87.70 | 5.76 | — | — | — | — | — | — |
| P/S Ratio | 6.23 | 4.81 | 3.34 | 4.67 | 4.79 | 20.94 | — | — | — | — | — |
| P/B Ratio | 7.92 | 5.74 | 3.22 | 2.87 | 2.66 | 4.36 | 3.50 | 2.65 | — | — | — |
| P/FCF | 166.24 | 128.20 | 55.59 | 95.78 | 185.01 | — | — | — | — | — | — |
| P/OCF | 164.45 | 126.82 | 55.00 | 94.84 | 181.66 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
KNSA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Kiniksa Pharmaceuticals, Ltd.'s enterprise value stands at 51.6x EBITDA, 11% below its 5-year average of 58.2x. The Healthcare sector median is 14.4x, placing the stock at a 259% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.58 | 2.93 | 4.31 | 4.26 | 17.92 | — | — | — | — | — |
| EV / EBITDA | 51.65 | 39.38 | — | — | 77.05 | — | — | — | — | — | — |
| EV / EBIT | 52.68 | 34.90 | — | — | 95.99 | — | — | — | — | — | — |
| EV / FCF | — | 122.06 | 48.76 | 88.52 | 164.52 | — | — | — | — | — | — |
KNSA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Kiniksa Pharmaceuticals, Ltd. earns an operating margin of 11.4%. Operating margins have expanded from -9.3% to 11.4% over the past 3 years, signaling improving operational efficiency. ROE of 11.7% is modest. ROIC of 17.1% represents solid returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 54.6% | 54.6% | 85.6% | 79.1% | 89.6% | 76.4% | — | — | — | — | — |
| Operating Margin | 11.4% | 11.4% | -10.8% | -9.3% | 4.4% | -406.4% | — | — | — | — | — |
| Net Profit Margin | 8.7% | 8.7% | -10.2% | 5.2% | 83.3% | -409.7% | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 11.7% | 11.7% | -9.8% | 3.4% | 63.1% | -63.6% | -60.1% | -1037.7% | — | — | — |
| ROA | 8.8% | 8.8% | -7.8% | 2.9% | 53.0% | -54.2% | -53.4% | -56.2% | -55.9% | -124.8% | -42.5% |
| ROIC | 17.1% | 17.1% | -11.3% | -6.1% | 4.2% | -85.9% | -61.1% | -70.4% | — | — | — |
| ROCE | 14.0% | 14.0% | -9.7% | -5.8% | 3.3% | -62.0% | -57.8% | -67.2% | -69.9% | -155.3% | -44.3% |
KNSA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Kiniksa Pharmaceuticals, Ltd. carries a Debt/EBITDA ratio of 0.1x, which is very conservative (96% below the sector average of 3.3x). The company holds a net cash position — cash of $166M exceeds total debt of $9M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.03 | 0.01 | 0.03 | 0.02 | 0.01 | — | — | — |
| Debt / EBITDA | 0.12 | 0.12 | — | — | 0.49 | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.28 | -0.40 | -0.22 | -0.29 | -0.63 | -0.34 | -0.20 | — | — | — |
| Net Debt / EBITDA | -1.98 | -1.98 | — | — | -9.59 | — | — | — | — | — | — |
| Debt / FCF | — | -6.14 | -6.84 | -7.27 | -20.48 | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($166M) exceeds total debt ($9M)
KNSA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Kiniksa Pharmaceuticals, Ltd.'s current ratio of 3.79x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 3.39x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 4.34x to 3.79x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.79 | 3.79 | 3.30 | 4.34 | 5.16 | 4.38 | 10.46 | 8.68 | 7.37 | 2.70 | 24.47 |
| Quick Ratio | 3.39 | 3.39 | 3.04 | 3.85 | 4.71 | 4.30 | 10.46 | 8.68 | 7.37 | 2.70 | 24.47 |
| Cash Ratio | 2.98 | 2.98 | 2.42 | 3.24 | 4.05 | 4.06 | 10.16 | 8.39 | 7.22 | 2.61 | 24.31 |
| Asset Turnover | — | 0.89 | 0.73 | 0.51 | 0.48 | 0.17 | — | — | — | — | — |
| Inventory Turnover | 5.60 | 5.60 | 2.31 | 1.82 | 1.06 | 2.48 | — | — | — | — | — |
| Days Sales Outstanding | — | 8.40 | 35.98 | 28.72 | 33.68 | 37.74 | — | — | — | — | — |
KNSA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Kiniksa Pharmaceuticals, Ltd. returns 0.2% to shareholders annually primarily through share buybacks. The earnings yield of 1.3% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.3% | 1.8% | — | 1.1% | 17.4% | — | — | — | — | — | — |
| FCF Yield | 0.6% | 0.8% | 1.8% | 1.0% | 0.5% | — | — | — | — | — | — |
| Buyback Yield | 0.2% | 0.2% | 0.4% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.2% | 0.2% | 0.4% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $79M | $71M | $72M | $70M | $69M | $62M | $54M | $30M | $32M | $32M |
Peer Comparison
Compare KNSA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 KNSAYou | $4B | 75.9 | 51.6 | 166.2 | 54.6% | 11.4% | 11.7% | 17.1% | 0.1 |
 ARDX | $2B | -26.8 | — | — | 89.5% | -10.1% | -36.2% | -10.7% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 CABA | $409M | -2.4 | — | — | — | — | -127.0% | -429.6% | — |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 AMRN | $309M | -8.2 | — | 45.8 | 56.6% | -6.5% | -8.2% | -2.9% | — |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 PTGX | $6B | -48.2 | — | 113.4 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 IQV | $30B | 22.8 | 13.0 | 14.8 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 10 years · Updated daily
See KNSA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KNSA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KNSA vs ARDX
Side-by-side business, growth, and profitability comparison vs Ardelyx, Inc..
Start ComparisonKNSA — Frequently Asked Questions
Quick answers to the most common questions about buying KNSA stock.
What is Kiniksa Pharmaceuticals, Ltd.'s P/E ratio?
Kiniksa Pharmaceuticals, Ltd.'s current P/E ratio is 75.9x. The historical average is 49.5x. This places it at the 67th percentile of its historical range.
What is Kiniksa Pharmaceuticals, Ltd.'s EV/EBITDA?
Kiniksa Pharmaceuticals, Ltd.'s current EV/EBITDA is 51.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 58.2x.
What is Kiniksa Pharmaceuticals, Ltd.'s ROE?
Kiniksa Pharmaceuticals, Ltd.'s return on equity (ROE) is 11.7%. The historical average is -9.2%.
Is KNSA stock overvalued?
Based on historical data, Kiniksa Pharmaceuticals, Ltd. is trading at a P/E of 75.9x. This is at the 67th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Kiniksa Pharmaceuticals, Ltd.'s profit margins?
Kiniksa Pharmaceuticals, Ltd. has 54.6% gross margin and 11.4% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Kiniksa Pharmaceuticals, Ltd. have?
Kiniksa Pharmaceuticals, Ltd.'s Debt/EBITDA ratio is 0.1x, indicating low leverage. A ratio below 2x is generally considered financially healthy.